As expected, treatment of subcutaneously implanted HepG2 cell tumor xenografts with metformin obviously prevented tumor growth and proliferation, as measured by Ki67 expression (Figure 6 and Figure S3). This evidence concerns the gene MKI67 and neoplasm.